C1QA and COMP: plasma-based biomarkers for early diagnosis of pancreatic neuroendocrine tumors.

ABSTRACT: Pancreatic Neuroendocrine tumors (PanNET) are challenging to diagnose and often detected at advanced stages due to a lack of specific and sensitive biomarkers. This study utilized proteomics as a valuable approach for cancer biomarker discovery; therefore, mass spectrometry-based proteomic profiling was conducted on plasma samples from 12 subjects (3 controls; 5 Grade I, 4 Grade II PanNET patients) to identify potential proteins capable of effectively distinguishing PanNET from healthy controls. Data are available via ProteomeXchange with the identifier PXD045045. 13.2% of proteins were uniquely identified in PanNET, while 60% were commonly expressed in PanNET and controls. 17 proteins exhibiting significant differential expression between PanNET and controls were identified with downstrea

SUBMITTER: Gorai PK 

PROVIDER: S-EPMC10686980 | biostudies-literature | 2023 Nov

REPOSITORIES: biostudies-literature